Ferulic acid ameliorates ulcerative colitis in a rat model via the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways and thus alleviating the inflammatory, oxidative and apoptotic conditions in the colon tissue
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
INTRODUCTION: Ulcerative colitis is a chronic inflammation of the colon. However, the common treatment for it is accompanied by many complications. Therefore, the present study was aimed to determine the ameliorative effects of ferulic acid on acetic acid-induced colitis in rat.
MATERIALS AND METHODS: To induce ulcerative colitis, animals received 0.8 ml of 7% acetic acid intra-rectally. Ferulic acid in 20, 40, and 60 mg/kg doses was administered orally one hour after the ulcerative colitis induction. Animals received treatments for five consecutive days and then were euthanized on the sixth day. The colon was dissected out and macroscopic lesions were examined. Colon samples were evaluated for histopathological examination, biochemical analysis, determination of the expression of inflammatory, and apoptotic genes as well as total antioxidant capacity.
RESULTS: Ferulic acid significantly inhibited inflammatory and apoptotic genes mRNA expression, also production of MDA and NO. Ferulic acid significantly increased the activity of antioxidant factors (TAC content, and SOD and CAT activity), thereby preventing inflammation and histopathological damage in the colon tissue of colitis rats.
CONCLUSION: The results of the present study confirmed the antioxidant, anti-inflammatory, and anti-apoptotic properties of ferulic acid. About the mechanism of action of this compound, it can be concluded that the ability of ferulic acid in the amelioration of ulcerative colitis is related to the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 31(2023), 5 vom: 01. Okt., Seite 2587-2597 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghasemi-Dehnoo, Maryam [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.09.2023 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10787-023-01277-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359335365 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359335365 | ||
| 003 | DE-627 | ||
| 005 | 20240118231854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-023-01277-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM359335365 | ||
| 035 | |a (NLM)37432553 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghasemi-Dehnoo, Maryam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ferulic acid ameliorates ulcerative colitis in a rat model via the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways and thus alleviating the inflammatory, oxidative and apoptotic conditions in the colon tissue |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2023 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a INTRODUCTION: Ulcerative colitis is a chronic inflammation of the colon. However, the common treatment for it is accompanied by many complications. Therefore, the present study was aimed to determine the ameliorative effects of ferulic acid on acetic acid-induced colitis in rat | ||
| 520 | |a MATERIALS AND METHODS: To induce ulcerative colitis, animals received 0.8 ml of 7% acetic acid intra-rectally. Ferulic acid in 20, 40, and 60 mg/kg doses was administered orally one hour after the ulcerative colitis induction. Animals received treatments for five consecutive days and then were euthanized on the sixth day. The colon was dissected out and macroscopic lesions were examined. Colon samples were evaluated for histopathological examination, biochemical analysis, determination of the expression of inflammatory, and apoptotic genes as well as total antioxidant capacity | ||
| 520 | |a RESULTS: Ferulic acid significantly inhibited inflammatory and apoptotic genes mRNA expression, also production of MDA and NO. Ferulic acid significantly increased the activity of antioxidant factors (TAC content, and SOD and CAT activity), thereby preventing inflammation and histopathological damage in the colon tissue of colitis rats | ||
| 520 | |a CONCLUSION: The results of the present study confirmed the antioxidant, anti-inflammatory, and anti-apoptotic properties of ferulic acid. About the mechanism of action of this compound, it can be concluded that the ability of ferulic acid in the amelioration of ulcerative colitis is related to the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apoptotic cytokines | |
| 650 | 4 | |a Ferulic acid | |
| 650 | 4 | |a Inflammatory cytokines | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Rat | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a ferulic acid |2 NLM | |
| 650 | 7 | |a AVM951ZWST |2 NLM | |
| 650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
| 650 | 7 | |a Lipopolysaccharides |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Acetic Acid |2 NLM | |
| 650 | 7 | |a Q40Q9N063P |2 NLM | |
| 700 | 1 | |a Amini-Khoei, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Lorigooini, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a AnjomShoa, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Rafieian-Kopaei, Mahmoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 31(2023), 5 vom: 01. Okt., Seite 2587-2597 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:5 |g day:01 |g month:10 |g pages:2587-2597 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-023-01277-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 5 |b 01 |c 10 |h 2587-2597 | ||